JNJ-69086420
janssen
['prostate']
phase 1 study of jnj-69086420, an actinium-225-labeled antibody targeting human kallikrein-2, for advanced #prostatecancer. presented by . #asco22 written coverage by &gt; 
Largest global online community of #urological medical professionals & patients. #AUA22 #bladdercancer #menshealth #prostatecancer #kidneycancer #Urology